ArticleCancer2019
Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013.
Article in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06381648 (An Exosome-based Liquid Biopsy Signature for Pre-operative Identification of Lymph Node Metastasis in Patients With Intrahepatic Cholangiocarcinoma), which is not on this map. Cited by 93 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Exosome-based Liquid Biopsy Signature for Pre-operative Identification of Lymph Node Metastasis in Patients With Intrahepatic Cholangiocarcinoma
Who cites it
93 citing papers in PubMed, 4 syntheses or guidelines pooled it, 161 citations in OpenAlex.
- A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada.Current oncology (Toronto, Ont.) · 2023Guideline
- Exogenous hormone use, reproductive factors and risk of intrahepatic cholangiocarcinoma among women: results from cohort studies in the Liver Cancer Pooling Project and the UK Biobank.British journal of cancer · 2020Pooled it
- Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Does high-grade dysplasia/carcinoma in situ of the biliary duct margin affect the prognosis of extrahepatic cholangiocarcinoma? A meta-analysis.World journal of surgical oncology · 2019Pooled it
- Tasurgratinib (E7090) for cholangiocarcinoma with fibroblast growth factor receptor 2 fusions/rearrangements: a multicenter, open-label, Phase 2 study.Japanese journal of clinical oncology · 2025Trial
- FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results.BMC cancer · 2020Trial
- Incidental/Misdiagnosed Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma in Patients Undergoing Living Donor Liver Transplantation.Journal of clinical medicine · 2026Article
- Article
- Immunohistochemical profiling of ampullary carcinoma: Molecular subtypes, prognostic markers, and the role of Claudin-18.Virchows Archiv : an international journal of pathology · 2026Article
- AI-assisted improvement of endoscopic diagnosis of ampullary lesions.NPJ digital medicine · 2026Article
- Perioperative approaches for patients with biliary tract cancer.Nature reviews. Clinical oncology · 2026Review
- Disparities in Gallbladder Cancer: Epidemiology, Molecular Mechanisms, and Clinical Implications.Molecular biology reports · 2026Review
- Article
- Endoscopic papillectomy for ampullary tumors: Multicenter retrospective study.Endoscopy international open · 2026Article
- Mortality trends of gallbladder cancer in middle-aged and older adults in the United States: a CDC WONDER analysis from 1999 to 2023.Frontiers in oncology · 2026Article
- Beyond futility: The history and potential of liver transplantation in cholangiocarcinoma.World journal of transplantation · 2025Review
- Berberine hydrochloride inhibits the proliferation and metastasis of p53 mutant gallbladder Cancer cells by regulating the IL6/STAT3 pathway.Scientific reports · 2025Article
- Global burden of early-onset gallbladder and biliary tract cancer from 1990 to 2021.BMC gastroenterology · 2025Article
- NUF2 and NEK2 promote malignant progression of gallbladder cancer by remodeling the extracellular matrix.Carcinogenesis · 2025Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundBiliary tract cancers (BTCs) are rare but deadly cancers (gallbladder cancer [GBC], intrahepatic cholangiocarcinoma [ICC], extrahepatic cholangiocarcinoma [ECC], and ampulla of Vater cancer [AVC]). A recent US study reported increasing GBC incidence among people younger than 45 years and blacks; however, it did not examine trends for other biliary tract sites.
methodsThis study characterized demographic differences in BTC incidence rates and time trends by anatomic site. Population-based North American Association of Central Cancer Registries data were used to calculate age-adjusted incidence rates, incidence rate ratios (IRRs), and estimated annual percent changes (eAPCs) for 1999-2013 by site and demographic group. For sites with significant differences in eAPC by age group, IRRs were compared by age group.
resultsGBC incidence rates declined among women (eAPC, -0.5%/y; P = .01) and all racial/ethnic groups except for non-Hispanic blacks, among whom rates increased (1.8%/y; P < .0001). Although GBC rates increased among 18- to 44-year-olds (eAPC, 1.8%/y; P = .01), they decreased among people 45 years old or older (-0.4%/y; P = .009). Sex (P < .0001) and racial/ethnic differences (P = .003 to .02) in GBC incidence were larger for younger people than older people. During this period, ICC (eAPC, 3.2%/y; P < .0001) and ECC rates (1.8%/y; P = .001) steadily increased across sex and racial/ethnic groups. Although AVC incidence rates increased among younger adults (eAPC, 1.8%/y; P = .03) but not older adults (-0.20%/y; P = .30), sex and racial/ethnic IRRs did not differ by age.
conclusionsDifferential patterns of BTC rates and temporal trends have been identified by anatomic site and demographic groups. These findings highlight the need for large pooling projects to evaluate BTC risk factors by anatomic site.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.